ASKA Pharmaceutical and Tokyo-based med tech Susmed said on January 28 that they have initiated a clinical study to evaluate the benefits of their investigational therapeutic app for premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD).The study will be conducted…
To read the full story
Related Article
- Susmed to Get 100 Million Yen Milestone after PMS App Trial Start
February 13, 2025
BUSINESS
- Sumitomo Regains Growth Momentum, Eyes 350 Billion Yen from 2 Key Drugs in FY2028
March 3, 2026
- Middle East Turmoil Raises Fears over API Shipments as Key Airports Shut
March 3, 2026
- UCB, Daiichi Sankyo to Wind Up Japan Partnership for Vimpat
March 3, 2026
- Itochu Snaps Up CoreMed to Bolster Japan Entry Support
March 3, 2026
- Ono to Transfer Opalmon, Prostandin to Daito by November
March 3, 2026
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…





